CTRI/2020/08/027246尚未招募不适用
Role of Tocilizumab in Patients with Moderate to Severe COVID-19 Pneumonia
GCS Medical College Hospital and Research Centre1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年1月9日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Role of Tocilizumab in COVID-19 Pneumonia
研究概览
简要总结
Tocilizumab is a humanized monoclonal antibody against IL-6 receptors. It has a proven role in Cytokine Releasing Syndrome, Rheumatoid Arthritis, and other autoimmune diseases.
COVID-19 virus primarily affects Respiratory system and may cause mild/moderate/severe Respiratory failure. To study the outcome in COVID pneumonia, giving Injectable Tocilizumab, 8mg/kg dosage in patients with moderate to severe COVID-19 Pneumonia.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •RT-PCR COVID-19 Test Positive patients will be included Moderate to Severe COVID Pneumonia patients will be included.
排除标准
- •Patients with Active Tuberculosis, Past history of Tuberculosis, Other active suspected Viral/Fungal infection, Platelet count <50,000/ml and Absolute Pneutrophil Count <1000/ml will be excluded.
结局指标
主要结局
Role of Tocilizumab in COVID-19 Pneumonia
时间窗: 3 months
次要结局
- To know the efficacy of Tocilizumab in COVID-19 Pneumonia patients(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Short-Term Application of Tocilizumab Following Myocardial InfarctionMyocardial InfarctionNCT02419937Keesler Air Force Base Medical Center28
终止
2 期
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)Glucocorticosteroid Refractory Acute GVHDNCT01757197Weill Medical College of Cornell University2
尚未招募
不适用
Role of Tocilizumab in COVID-19 Pneumonia patientsCTRI/2020/08/027246GCS Medical College Hospital and Research Centre
Unknown
2 期
Efficacy and Safety of Tocilizumab in Adult's Still DiseaseAdult's Still DiseaseNCT01002781Tel-Aviv Sourasky Medical Center10
Unknown
4 期
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.Giant Cell ArteritisNCT03244709Hospital of Prato15